[go: up one dir, main page]

MX2010002081A - Procesos para la preparacion de formas a, b cristalinas y de la forma a cristalina pura de erlotinib hc1. - Google Patents

Procesos para la preparacion de formas a, b cristalinas y de la forma a cristalina pura de erlotinib hc1.

Info

Publication number
MX2010002081A
MX2010002081A MX2010002081A MX2010002081A MX2010002081A MX 2010002081 A MX2010002081 A MX 2010002081A MX 2010002081 A MX2010002081 A MX 2010002081A MX 2010002081 A MX2010002081 A MX 2010002081A MX 2010002081 A MX2010002081 A MX 2010002081A
Authority
MX
Mexico
Prior art keywords
processes
preparation
erlotinib hcl
crystalline form
pure
Prior art date
Application number
MX2010002081A
Other languages
English (en)
Inventor
Augusto Canavesi
Jiri Faustmann
Ales Gavenda
Dietmar Flubacher
Original Assignee
Plus Chemicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plus Chemicals Sa filed Critical Plus Chemicals Sa
Publication of MX2010002081A publication Critical patent/MX2010002081A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención proporciona procesos para preparar las Formas A, B cristalinas y la Forma A cristalina de clorhidrato de erlotinib.
MX2010002081A 2007-08-23 2008-08-25 Procesos para la preparacion de formas a, b cristalinas y de la forma a cristalina pura de erlotinib hc1. MX2010002081A (es)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US95758507P 2007-08-23 2007-08-23
US96820707P 2007-08-27 2007-08-27
US98434807P 2007-10-31 2007-10-31
US99081307P 2007-11-28 2007-11-28
US1816007P 2007-12-31 2007-12-31
US5294308P 2008-05-13 2008-05-13
US12865808P 2008-05-22 2008-05-22
US5920408P 2008-06-05 2008-06-05
US7399008P 2008-06-19 2008-06-19
US7517408P 2008-06-24 2008-06-24
US8267108P 2008-07-22 2008-07-22
PCT/US2008/010083 WO2009025873A2 (en) 2007-08-23 2008-08-25 Processes for the preparation of crystalline forms a, b and pure crystalline form a of erlotinib hcl

Publications (1)

Publication Number Publication Date
MX2010002081A true MX2010002081A (es) 2010-06-01

Family

ID=40101153

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002081A MX2010002081A (es) 2007-08-23 2008-08-25 Procesos para la preparacion de formas a, b cristalinas y de la forma a cristalina pura de erlotinib hc1.

Country Status (5)

Country Link
US (1) US20090131665A1 (es)
EP (2) EP2183226A2 (es)
MX (1) MX2010002081A (es)
TW (3) TW200925151A (es)
WO (3) WO2009025875A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2411373B1 (en) 2009-03-26 2015-10-21 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
DE202010006543U1 (de) 2010-05-07 2010-09-09 Ratiopharm Gmbh Erlotinibresinat
NZ606042A (en) 2010-07-23 2015-05-29 Generics Uk Ltd Process for the preparation of erlotinib and salts thereof
US20140121373A1 (en) 2011-05-03 2014-05-01 Cadila Healthcare Limited Process for preparing stable polymorphic form of erlotinib hydrochloride
CN103360325A (zh) * 2012-03-26 2013-10-23 重庆医药工业研究院有限责任公司 一种盐酸厄洛替尼晶型a的制备方法
CN103420922B (zh) * 2012-05-18 2016-08-31 重庆华邦制药有限公司 一种工业化生产盐酸厄洛替尼b型晶的方法
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
CN103110597B (zh) * 2013-02-02 2018-04-13 浙江华海药业股份有限公司 盐酸厄洛替尼片及其制备方法
WO2014136126A2 (en) * 2013-03-08 2014-09-12 Laurus Labs Private Limited A process for preparing erlotinib hydrochloride form a
CN104072427B (zh) * 2013-03-29 2019-05-28 江苏豪森药业集团有限公司 盐酸厄洛替尼晶型的制备方法
CN103159685A (zh) * 2013-04-11 2013-06-19 苏州立新制药有限公司 4-氯-6，7-二(2-甲氧基乙氧基)喹唑啉的制备方法
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
CN103508962B (zh) * 2013-07-03 2016-04-13 山东金城医药化工股份有限公司 盐酸厄洛替尼b晶型的制备方法
CN103641786A (zh) * 2013-12-26 2014-03-19 山东博迈康药物研究有限公司 一种盐酸厄洛替尼a晶型的制备方法
RU2610337C1 (ru) * 2015-12-10 2017-02-09 Индивидуальный предприниматель Михайлов Олег Ростиславович Кристаллическая β-модификация N-(3-этинилфенил)-6,7-бис(2 метоксиэтокси)хиназолин-4-амин гидрохлорида, способ её получения и фармацевтическая композиция на её основе
JP2019059685A (ja) * 2017-09-26 2019-04-18 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
RS49836B (sr) * 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
NZ551406A (en) * 2004-06-03 2010-03-26 Hoffmann La Roche Treatment of non small cell lung cancer with gemcitabine and erlotinib (an egfr kinase inhibitor)
AU2006235487B2 (en) * 2005-04-12 2011-12-22 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
WO2007060691A2 (en) * 2005-11-23 2007-05-31 Natco Pharma Limited A novel process for the preparation of erlotinib
WO2008102369A1 (en) * 2007-02-21 2008-08-28 Natco Pharma Limited Novel polymorphs of erlotinib hydrochloride and method of preparation

Also Published As

Publication number Publication date
WO2009025876A3 (en) 2009-08-20
TW200925151A (en) 2009-06-16
WO2009025875A1 (en) 2009-02-26
WO2009025876A8 (en) 2010-03-04
WO2009025873A2 (en) 2009-02-26
WO2009025876A2 (en) 2009-02-26
US20090131665A1 (en) 2009-05-21
TW200925152A (en) 2009-06-16
TW200927732A (en) 2009-07-01
EP2183226A2 (en) 2010-05-12
EP2181099A2 (en) 2010-05-05
WO2009025873A3 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
MX2010002081A (es) Procesos para la preparacion de formas a, b cristalinas y de la forma a cristalina pura de erlotinib hc1.
TW200716512A (en) Processes for preparing cinacalcet hydrochloride crystal form I
WO2009084024A3 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
EP2460797A3 (en) Process for preparation of ivabradine hydrochloride
IL183237A0 (en) Polymorphs of memantine hydrochloride
MX2009006252A (es) Sal de tanato de rasagilina.
WO2010054056A3 (en) Nilotinib hci crystalline forms
EP2167449A4 (en) PROCESSES FOR PREPARING 1,1,2,3-TETRACHLOROPROPENE
MX2010002836A (es) Bortezomib y proceso para la produccion del mismo.
MX2009012561A (es) Formas polimorficas y amorfas de esteviosida, metodos para su formulacion, y usos.
IL204555A0 (en) (carboxylalkylene-phenyl) phenyl-oxalamides, method for the production thereof, and use of same as a medicatment
IL210447A0 (en) Icotinib hydrochloride, synthesis, crystalline forms, drug combinations, and uses thereof
ZA201001014B (en) (Cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
MX2011006334A (es) Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c] [1,2]-oxaborol-1-ol.
WO2008021342A3 (en) Amorphous and crystalline forms of 9-hydroxy-risperidone ( paliperidone )
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
PL2146944T3 (pl) Sposób otrzymywania folianów znakowanych fluorem-18
TW200833649A (en) Method for the preparation of hydroxyadamantanamine
WO2011058525A3 (en) Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
IL186220A0 (en) Processes for the preparation of atomoxetine hydrochloride
WO2011018771A3 (en) Process for the preparation of valganciclovir hydrochloride
GB2448073B (en) Pneumatic tappet adjustment tool
PH12013500210A1 (en) Highly crystalline valsartan
EG25292A (en) Process for the production of anilines.
TW200637832A (en) Process for preparing amorphous valsartan

Legal Events

Date Code Title Description
FA Abandonment or withdrawal